Overview

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of 0.25% Reproxalap Ophthalmic Solution in Subjects with Dry Eye Disease

Phase:

Phase 3

Details

Lead Sponsor:

Aldeyra Therapeutics, Inc.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions